How many clinical trials are tracked for Invasive candidiasis?

12 trials are tracked, 1 with published results.

Invasive candidiasis Research

Invasive candidiasis: what the trials found

Clinical evaluations of invasive candidiasis show varying success rates across different antifungal agents. Isavuconazole demonstrated overall response success rates at the end of intravenous therapy (EOIV) of 60.3% and 71.1% ³. Anidulafungin showed a global treatment response success rate of 69.5% at the end of treatment, with 70.7% success at EOIV and 60.2% success two weeks after treatment ⁶.

Caspofungin was evaluated in multiple studies; one trial reported an overall favorable response to therapy of 66.7% and 62.5% ¹⁰, while another study confirmed its use for the condition ⁷. Ibrexafungerp showed global response rates varying by enrollment category, including results of 74%, 41%, 13%, 95%, 29%, and 10% ⁴.

Early-phase data for SCY-078 indicated a 21% global success rate at the end of treatment with only a 1% recurrence rate of baseline fungal infection ⁵, while another study also evaluated this agent ⁸. Laboratory data for anidulafungin showed specific changes in chemistry laboratory test data, though these values varied across different metrics ².

For the clinician treating this condition

Isavuconazole and Anidulafungin both demonstrate high rates of global treatment success at the end of intravenous therapy (60.3% to 71.1% and 69.5% to 70.7%, respectively) [3, 6].
Caspofungin is associated with an overall favorable response rate of approximately 62.5% to 66.7% in clinical settings ¹⁰.
Ibrexafungerp shows highly variable global response rates depending on the specific patient enrollment category ⁴.

AI synthesis of 8 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.